West Pharmaceutical (WST) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Contract Manufactured ProductsProprietary Products
0125M250M375M500M625M750M875M1BQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0250M500M750M1B1B2B2B2BQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
01122344556687990Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesSelling General And Administrative Expenses
025M50M75M100M125M150M175M200MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
038M75M112M150M188M225M262M300MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

EPSEPS Diluted
011223445Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue Variation (%)

Revenue Variation
-8-4-12610131620Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
0255075100125150175200Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-12471012151720Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0918263544526170Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
0815223038455260Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0918263544526170Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
050M100M150M200M250M300M350M400MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
050M100M150M200M250M300M350M400MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Cash Flow to Debt Ratio

Cash At End Of Period
0100M200M300M400M500M600M700M800MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics